Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases.
To evaluate the activity of posaconazole for treatment of zygomycosis, a disease for which therapeutic options are limited, we conducted a retrospective study including 91 patients with zygomycosis (proven zygomycosis, 69 patients; probable zygomycosis, 22 patients). Patients had infection that was refractory to prior antifungal treatment (n=81) or were intolerant of such treatment (n=10) and participated in the compassionate-use posaconazole (800 mg/day) program. The rate of success (i.e., either complete or partial response) at 12 weeks after treatment initiation was 60%, and 21% of patients had stable disease. The overall high success and survival rates reported here provide encouraging data regarding posaconazole as an alternative therapy for zygomycosis.
van Burik
Jo-Anne H
JA
University of Minnesota, Minneapolis, Minnesota, USA.
Hare
Roberta S
RS
Solomon
Howard F
HF
Corrado
Michael L
ML
Kontoyiannis
Dimitrios P
DP
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000935:Antifungal Agents / Q000627:therapeutic use*; D002648:Child; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D016879:Salvage Therapy; D014230:Triazoles / Q000627:therapeutic use*; D020096:Zygomycosis / Q000188:drug therapy*
D000935:Antifungal Agents; D014230:Triazoles; C101425:posaconazole